Genocea
BioTech/Drugs - Cambridge, Massachusetts, US
Genocea Details
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
Genocea Technologies
Email Providers
Mimecast
Load Balancers
Nginx
CMS
WP Engine
Hosting
Google Cloud Hosting
Other
Mobile Friendly